nodes	percent_of_prediction	percent_of_DWPC	metapath
Adenosine—ADA—Validated transcriptional targets of TAp63 isoforms—TFAP2C—testicular cancer	0.0228	0.2	CbGpPWpGaD
Adenosine—SLC28A3—female gonad—testicular cancer	0.0181	0.0935	CbGeAlD
Adenosine—DPP4—embryo—testicular cancer	0.017	0.0875	CbGeAlD
Adenosine—ADK—seminal vesicle—testicular cancer	0.0164	0.0847	CbGeAlD
Adenosine—DPP4—seminal vesicle—testicular cancer	0.0159	0.0822	CbGeAlD
Adenosine—ADORA2A—gonad—testicular cancer	0.0132	0.0682	CbGeAlD
Adenosine—ADK—gonad—testicular cancer	0.0119	0.0612	CbGeAlD
Adenosine—ADORA2B—testis—testicular cancer	0.0115	0.0591	CbGeAlD
Adenosine—ADA—testis—testicular cancer	0.0105	0.054	CbGeAlD
Adenosine—ADK—female gonad—testicular cancer	0.00965	0.0498	CbGeAlD
Adenosine—ADORA2A—testis—testicular cancer	0.00953	0.0491	CbGeAlD
Adenosine—DPP4—female gonad—testicular cancer	0.00936	0.0482	CbGeAlD
Adenosine—SLC28A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00874	0.0766	CbGpPWpGaD
Adenosine—ADK—testis—testicular cancer	0.00856	0.0441	CbGeAlD
Adenosine—DPP4—testis—testicular cancer	0.0083	0.0428	CbGeAlD
Adenosine—ADORA1—testis—testicular cancer	0.00823	0.0424	CbGeAlD
Adenosine—ADORA2B—G alpha (s) signalling events—INSL3—testicular cancer	0.00779	0.0683	CbGpPWpGaD
Adenosine—ADA—lymph node—testicular cancer	0.0076	0.0392	CbGeAlD
Adenosine—ADK—lymph node—testicular cancer	0.00621	0.032	CbGeAlD
Adenosine—DPP4—lymph node—testicular cancer	0.00602	0.031	CbGeAlD
Adenosine—ADORA1—lymph node—testicular cancer	0.00597	0.0308	CbGeAlD
Adenosine—ADA—C-MYB transcription factor network—MAD1L1—testicular cancer	0.00558	0.0489	CbGpPWpGaD
Adenosine—ADORA2A—G alpha (s) signalling events—INSL3—testicular cancer	0.00511	0.0448	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—MAD1L1—testicular cancer	0.00488	0.0428	CbGpPWpGaD
Adenosine—SLC28A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00444	0.0389	CbGpPWpGaD
Adenosine—ADA—C-MYB transcription factor network—H2AFZ—testicular cancer	0.00389	0.0341	CbGpPWpGaD
Adenosine—ADORA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00371	0.0326	CbGpPWpGaD
Adenosine—ADA—C-MYB transcription factor network—KITLG—testicular cancer	0.00358	0.0314	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—H2AFZ—testicular cancer	0.0034	0.0298	CbGpPWpGaD
Adenosine—ADORA1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00316	0.0277	CbGpPWpGaD
Adenosine—ADORA2B—C-MYB transcription factor network—KITLG—testicular cancer	0.00313	0.0275	CbGpPWpGaD
Adenosine—ADORA2B—GPCR ligand binding—INSL3—testicular cancer	0.00283	0.0248	CbGpPWpGaD
Adenosine—ADA—C-MYB transcription factor network—KIT—testicular cancer	0.00244	0.0214	CbGpPWpGaD
Adenosine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00244	0.0214	CbGpPWpGaD
Adenosine—ADORA1—GPCR ligand binding—INSL3—testicular cancer	0.0024	0.0211	CbGpPWpGaD
Adenosine—Acute coronary syndrome—Etoposide—testicular cancer	0.00234	0.00338	CcSEcCtD
Adenosine—Chest pain—Bleomycin—testicular cancer	0.00234	0.00337	CcSEcCtD
Adenosine—Myocardial infarction—Etoposide—testicular cancer	0.00232	0.00336	CcSEcCtD
Adenosine—Discomfort—Bleomycin—testicular cancer	0.00231	0.00333	CcSEcCtD
Adenosine—Urticaria—Chlorambucil—testicular cancer	0.0023	0.00332	CcSEcCtD
Adenosine—Pain—Vinblastine—testicular cancer	0.00227	0.00328	CcSEcCtD
Adenosine—Atrioventricular block—Doxorubicin—testicular cancer	0.00226	0.00327	CcSEcCtD
Adenosine—Anaphylactic shock—Bleomycin—testicular cancer	0.00224	0.00324	CcSEcCtD
Adenosine—Vision blurred—Ifosfamide—testicular cancer	0.00221	0.00319	CcSEcCtD
Adenosine—Ventricular tachycardia—Doxorubicin—testicular cancer	0.0022	0.00317	CcSEcCtD
Adenosine—Injection site reaction—Doxorubicin—testicular cancer	0.00218	0.00316	CcSEcCtD
Adenosine—Tinnitus—Cisplatin—testicular cancer	0.00216	0.00313	CcSEcCtD
Adenosine—Cardiac disorder—Cisplatin—testicular cancer	0.00215	0.00311	CcSEcCtD
Adenosine—Flushing—Cisplatin—testicular cancer	0.00215	0.00311	CcSEcCtD
Adenosine—Agitation—Ifosfamide—testicular cancer	0.00215	0.00311	CcSEcCtD
Adenosine—Discomfort—Dactinomycin—testicular cancer	0.00215	0.00311	CcSEcCtD
Adenosine—Angioedema—Ifosfamide—testicular cancer	0.00214	0.0031	CcSEcCtD
Adenosine—ADORA2B—C-MYB transcription factor network—KIT—testicular cancer	0.00214	0.0187	CbGpPWpGaD
Adenosine—Hypersensitivity—Chlorambucil—testicular cancer	0.00213	0.00308	CcSEcCtD
Adenosine—Hypoaesthesia—Etoposide—testicular cancer	0.00212	0.00306	CcSEcCtD
Adenosine—Mediastinal disorder—Cisplatin—testicular cancer	0.00209	0.00302	CcSEcCtD
Adenosine—Hypotension—Bleomycin—testicular cancer	0.00209	0.00302	CcSEcCtD
Adenosine—Asthenia—Chlorambucil—testicular cancer	0.00208	0.003	CcSEcCtD
Adenosine—Arrhythmia—Cisplatin—testicular cancer	0.00207	0.003	CcSEcCtD
Adenosine—Palpitations—Ifosfamide—testicular cancer	0.00207	0.00299	CcSEcCtD
Adenosine—Cough—Ifosfamide—testicular cancer	0.00205	0.00296	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00204	0.00295	CcSEcCtD
Adenosine—Convulsion—Ifosfamide—testicular cancer	0.00203	0.00294	CcSEcCtD
Adenosine—Hypertension—Ifosfamide—testicular cancer	0.00202	0.00292	CcSEcCtD
Adenosine—Paraesthesia—Bleomycin—testicular cancer	0.00201	0.00291	CcSEcCtD
Adenosine—Dyspnoea—Bleomycin—testicular cancer	0.002	0.00288	CcSEcCtD
Adenosine—Chest pain—Ifosfamide—testicular cancer	0.002	0.00288	CcSEcCtD
Adenosine—Cardiac disorder—Etoposide—testicular cancer	0.00197	0.00285	CcSEcCtD
Adenosine—Flushing—Etoposide—testicular cancer	0.00197	0.00285	CcSEcCtD
Adenosine—Discomfort—Ifosfamide—testicular cancer	0.00197	0.00285	CcSEcCtD
Adenosine—Hypersensitivity—Vinblastine—testicular cancer	0.00195	0.00282	CcSEcCtD
Adenosine—Mediastinal disorder—Etoposide—testicular cancer	0.00192	0.00277	CcSEcCtD
Adenosine—Pain—Bleomycin—testicular cancer	0.00191	0.00277	CcSEcCtD
Adenosine—Anaphylactic shock—Ifosfamide—testicular cancer	0.00191	0.00276	CcSEcCtD
Adenosine—Vision blurred—Cisplatin—testicular cancer	0.0019	0.00275	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.0019	0.00275	CcSEcCtD
Adenosine—Asthenia—Vinblastine—testicular cancer	0.0019	0.00275	CcSEcCtD
Adenosine—Tremor—Cisplatin—testicular cancer	0.00189	0.00274	CcSEcCtD
Adenosine—Cerebrovascular accident—Methotrexate—testicular cancer	0.00188	0.00272	CcSEcCtD
Adenosine—ADORA2A—GPCR ligand binding—INSL3—testicular cancer	0.00186	0.0163	CbGpPWpGaD
Adenosine—Hyperhidrosis—Ifosfamide—testicular cancer	0.00185	0.00267	CcSEcCtD
Adenosine—Vomiting—Chlorambucil—testicular cancer	0.00184	0.00266	CcSEcCtD
Adenosine—Dysgeusia—Etoposide—testicular cancer	0.00181	0.00262	CcSEcCtD
Adenosine—Back pain—Etoposide—testicular cancer	0.00179	0.00259	CcSEcCtD
Adenosine—Hypotension—Ifosfamide—testicular cancer	0.00179	0.00258	CcSEcCtD
Adenosine—Pain—Dactinomycin—testicular cancer	0.00179	0.00258	CcSEcCtD
Adenosine—Urticaria—Bleomycin—testicular cancer	0.00178	0.00257	CcSEcCtD
Adenosine—Cardiac failure—Epirubicin—testicular cancer	0.00177	0.00255	CcSEcCtD
Adenosine—Cerebrovascular accident—Epirubicin—testicular cancer	0.00176	0.00254	CcSEcCtD
Adenosine—Dizziness—Vinblastine—testicular cancer	0.00175	0.00253	CcSEcCtD
Adenosine—Convulsion—Cisplatin—testicular cancer	0.00175	0.00253	CcSEcCtD
Adenosine—Mood swings—Methotrexate—testicular cancer	0.00174	0.00252	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00174	0.00252	CcSEcCtD
Adenosine—Nausea—Chlorambucil—testicular cancer	0.00172	0.00248	CcSEcCtD
Adenosine—Paraesthesia—Ifosfamide—testicular cancer	0.00172	0.00248	CcSEcCtD
Adenosine—Anxiety—Cisplatin—testicular cancer	0.00171	0.00248	CcSEcCtD
Adenosine—Dyspnoea—Ifosfamide—testicular cancer	0.00171	0.00247	CcSEcCtD
Adenosine—Somnolence—Ifosfamide—testicular cancer	0.0017	0.00246	CcSEcCtD
Adenosine—Discomfort—Cisplatin—testicular cancer	0.0017	0.00246	CcSEcCtD
Adenosine—Affect lability—Epirubicin—testicular cancer	0.0017	0.00245	CcSEcCtD
Adenosine—Vomiting—Vinblastine—testicular cancer	0.00169	0.00244	CcSEcCtD
Adenosine—Headache—Vinblastine—testicular cancer	0.00166	0.0024	CcSEcCtD
Adenosine—Anaphylactic shock—Cisplatin—testicular cancer	0.00165	0.00238	CcSEcCtD
Adenosine—Hypersensitivity—Bleomycin—testicular cancer	0.00165	0.00238	CcSEcCtD
Adenosine—Cardiac arrest—Epirubicin—testicular cancer	0.00164	0.00237	CcSEcCtD
Adenosine—Pain—Ifosfamide—testicular cancer	0.00164	0.00236	CcSEcCtD
Adenosine—Cardiac failure—Doxorubicin—testicular cancer	0.00163	0.00236	CcSEcCtD
Adenosine—Mood swings—Epirubicin—testicular cancer	0.00163	0.00236	CcSEcCtD
Adenosine—Loss of consciousness—Etoposide—testicular cancer	0.00163	0.00235	CcSEcCtD
Adenosine—Cerebrovascular accident—Doxorubicin—testicular cancer	0.00163	0.00235	CcSEcCtD
Adenosine—Cough—Etoposide—testicular cancer	0.00162	0.00233	CcSEcCtD
Adenosine—Tachycardia—Cisplatin—testicular cancer	0.00161	0.00233	CcSEcCtD
Adenosine—Asthenia—Bleomycin—testicular cancer	0.00161	0.00232	CcSEcCtD
Adenosine—Convulsion—Etoposide—testicular cancer	0.0016	0.00232	CcSEcCtD
Adenosine—Hypertension—Etoposide—testicular cancer	0.0016	0.00231	CcSEcCtD
Adenosine—ADORA2B—GPCR downstream signaling—INSL3—testicular cancer	0.0016	0.014	CbGpPWpGaD
Adenosine—Hyperhidrosis—Cisplatin—testicular cancer	0.00159	0.0023	CcSEcCtD
Adenosine—Chest pain—Etoposide—testicular cancer	0.00158	0.00228	CcSEcCtD
Adenosine—Nausea—Vinblastine—testicular cancer	0.00157	0.00228	CcSEcCtD
Adenosine—Affect lability—Doxorubicin—testicular cancer	0.00157	0.00227	CcSEcCtD
Adenosine—Discomfort—Etoposide—testicular cancer	0.00156	0.00225	CcSEcCtD
Adenosine—Hypotension—Cisplatin—testicular cancer	0.00154	0.00223	CcSEcCtD
Adenosine—Hypersensitivity—Dactinomycin—testicular cancer	0.00154	0.00222	CcSEcCtD
Adenosine—Abdominal discomfort—Methotrexate—testicular cancer	0.00153	0.00221	CcSEcCtD
Adenosine—Urticaria—Ifosfamide—testicular cancer	0.00152	0.0022	CcSEcCtD
Adenosine—Cardiac arrest—Doxorubicin—testicular cancer	0.00152	0.00219	CcSEcCtD
Adenosine—Anaphylactic shock—Etoposide—testicular cancer	0.00151	0.00218	CcSEcCtD
Adenosine—Mood swings—Doxorubicin—testicular cancer	0.00151	0.00218	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.0015	0.00217	CcSEcCtD
Adenosine—Asthenia—Dactinomycin—testicular cancer	0.0015	0.00216	CcSEcCtD
Adenosine—Paraesthesia—Cisplatin—testicular cancer	0.00148	0.00214	CcSEcCtD
Adenosine—Tachycardia—Etoposide—testicular cancer	0.00147	0.00213	CcSEcCtD
Adenosine—Dyspnoea—Cisplatin—testicular cancer	0.00147	0.00213	CcSEcCtD
Adenosine—Hyperhidrosis—Etoposide—testicular cancer	0.00146	0.00211	CcSEcCtD
Adenosine—ADORA2B—Signaling by GPCR—INSL3—testicular cancer	0.00145	0.0127	CbGpPWpGaD
Adenosine—Vomiting—Bleomycin—testicular cancer	0.00142	0.00206	CcSEcCtD
Adenosine—Drowsiness—Methotrexate—testicular cancer	0.00142	0.00205	CcSEcCtD
Adenosine—Hypotension—Etoposide—testicular cancer	0.00141	0.00204	CcSEcCtD
Adenosine—Rash—Bleomycin—testicular cancer	0.00141	0.00204	CcSEcCtD
Adenosine—Pain—Cisplatin—testicular cancer	0.00141	0.00204	CcSEcCtD
Adenosine—Dermatitis—Bleomycin—testicular cancer	0.00141	0.00204	CcSEcCtD
Adenosine—Hypersensitivity—Ifosfamide—testicular cancer	0.00141	0.00204	CcSEcCtD
Adenosine—Pollakiuria—Epirubicin—testicular cancer	0.00138	0.00199	CcSEcCtD
Adenosine—Asthenia—Ifosfamide—testicular cancer	0.00137	0.00198	CcSEcCtD
Adenosine—Sweating—Methotrexate—testicular cancer	0.00136	0.00197	CcSEcCtD
Adenosine—ADORA1—GPCR downstream signaling—INSL3—testicular cancer	0.00136	0.0119	CbGpPWpGaD
Adenosine—Paraesthesia—Etoposide—testicular cancer	0.00136	0.00196	CcSEcCtD
Adenosine—Dyspnoea—Etoposide—testicular cancer	0.00135	0.00195	CcSEcCtD
Adenosine—Somnolence—Etoposide—testicular cancer	0.00134	0.00194	CcSEcCtD
Adenosine—Nausea—Bleomycin—testicular cancer	0.00133	0.00192	CcSEcCtD
Adenosine—Drowsiness—Epirubicin—testicular cancer	0.00133	0.00192	CcSEcCtD
Adenosine—Vomiting—Dactinomycin—testicular cancer	0.00133	0.00192	CcSEcCtD
Adenosine—Rash—Dactinomycin—testicular cancer	0.00132	0.0019	CcSEcCtD
Adenosine—Pain—Etoposide—testicular cancer	0.00129	0.00187	CcSEcCtD
Adenosine—Sweating—Epirubicin—testicular cancer	0.00127	0.00184	CcSEcCtD
Adenosine—Pollakiuria—Doxorubicin—testicular cancer	0.00127	0.00184	CcSEcCtD
Adenosine—Dizziness—Ifosfamide—testicular cancer	0.00127	0.00183	CcSEcCtD
Adenosine—Nausea—Dactinomycin—testicular cancer	0.00124	0.00179	CcSEcCtD
Adenosine—ADORA1—Signaling by GPCR—INSL3—testicular cancer	0.00123	0.0108	CbGpPWpGaD
Adenosine—Drowsiness—Doxorubicin—testicular cancer	0.00123	0.00178	CcSEcCtD
Adenosine—Vomiting—Ifosfamide—testicular cancer	0.00122	0.00176	CcSEcCtD
Adenosine—Hypersensitivity—Cisplatin—testicular cancer	0.00122	0.00176	CcSEcCtD
Adenosine—Bradycardia—Epirubicin—testicular cancer	0.00121	0.00175	CcSEcCtD
Adenosine—Rash—Ifosfamide—testicular cancer	0.00121	0.00174	CcSEcCtD
Adenosine—Dermatitis—Ifosfamide—testicular cancer	0.00121	0.00174	CcSEcCtD
Adenosine—Urticaria—Etoposide—testicular cancer	0.0012	0.00173	CcSEcCtD
Adenosine—Tinnitus—Methotrexate—testicular cancer	0.00119	0.00172	CcSEcCtD
Adenosine—Hypoaesthesia—Epirubicin—testicular cancer	0.00119	0.00171	CcSEcCtD
Adenosine—Asthenia—Cisplatin—testicular cancer	0.00118	0.00171	CcSEcCtD
Adenosine—Cardiac disorder—Methotrexate—testicular cancer	0.00118	0.00171	CcSEcCtD
Adenosine—Sweating—Doxorubicin—testicular cancer	0.00118	0.0017	CcSEcCtD
Adenosine—Mediastinal disorder—Methotrexate—testicular cancer	0.00115	0.00166	CcSEcCtD
Adenosine—Nausea—Ifosfamide—testicular cancer	0.00114	0.00164	CcSEcCtD
Adenosine—Bradycardia—Doxorubicin—testicular cancer	0.00112	0.00162	CcSEcCtD
Adenosine—Hypersensitivity—Etoposide—testicular cancer	0.00111	0.00161	CcSEcCtD
Adenosine—Tinnitus—Epirubicin—testicular cancer	0.00111	0.00161	CcSEcCtD
Adenosine—Flushing—Epirubicin—testicular cancer	0.00111	0.0016	CcSEcCtD
Adenosine—Cardiac disorder—Epirubicin—testicular cancer	0.00111	0.0016	CcSEcCtD
Adenosine—Hypoaesthesia—Doxorubicin—testicular cancer	0.0011	0.00159	CcSEcCtD
Adenosine—Dysgeusia—Methotrexate—testicular cancer	0.00109	0.00157	CcSEcCtD
Adenosine—Asthenia—Etoposide—testicular cancer	0.00108	0.00157	CcSEcCtD
Adenosine—Mediastinal disorder—Epirubicin—testicular cancer	0.00107	0.00155	CcSEcCtD
Adenosine—Back pain—Methotrexate—testicular cancer	0.00107	0.00155	CcSEcCtD
Adenosine—Arrhythmia—Epirubicin—testicular cancer	0.00107	0.00154	CcSEcCtD
Adenosine—ADORA2A—GPCR downstream signaling—INSL3—testicular cancer	0.00105	0.0092	CbGpPWpGaD
Adenosine—Vomiting—Cisplatin—testicular cancer	0.00105	0.00152	CcSEcCtD
Adenosine—Vision blurred—Methotrexate—testicular cancer	0.00105	0.00151	CcSEcCtD
Adenosine—Rash—Cisplatin—testicular cancer	0.00104	0.0015	CcSEcCtD
Adenosine—Dermatitis—Cisplatin—testicular cancer	0.00104	0.0015	CcSEcCtD
Adenosine—Tinnitus—Doxorubicin—testicular cancer	0.00103	0.00149	CcSEcCtD
Adenosine—Cardiac disorder—Doxorubicin—testicular cancer	0.00102	0.00148	CcSEcCtD
Adenosine—Flushing—Doxorubicin—testicular cancer	0.00102	0.00148	CcSEcCtD
Adenosine—Tension—Epirubicin—testicular cancer	0.00102	0.00147	CcSEcCtD
Adenosine—Dysgeusia—Epirubicin—testicular cancer	0.00102	0.00147	CcSEcCtD
Adenosine—Nervousness—Epirubicin—testicular cancer	0.00101	0.00146	CcSEcCtD
Adenosine—Back pain—Epirubicin—testicular cancer	0.001	0.00145	CcSEcCtD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.001	0.00879	CbGpPWpGaD
Adenosine—Dizziness—Etoposide—testicular cancer	0.000999	0.00144	CcSEcCtD
Adenosine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000994	0.00144	CcSEcCtD
Adenosine—Arrhythmia—Doxorubicin—testicular cancer	0.000985	0.00142	CcSEcCtD
Adenosine—Nausea—Cisplatin—testicular cancer	0.00098	0.00142	CcSEcCtD
Adenosine—Vision blurred—Epirubicin—testicular cancer	0.000978	0.00141	CcSEcCtD
Adenosine—Cough—Methotrexate—testicular cancer	0.000968	0.0014	CcSEcCtD
Adenosine—Convulsion—Methotrexate—testicular cancer	0.000961	0.00139	CcSEcCtD
Adenosine—Vomiting—Etoposide—testicular cancer	0.000961	0.00139	CcSEcCtD
Adenosine—Agitation—Epirubicin—testicular cancer	0.000954	0.00138	CcSEcCtD
Adenosine—Rash—Etoposide—testicular cancer	0.000953	0.00138	CcSEcCtD
Adenosine—ADORA2A—Signaling by GPCR—INSL3—testicular cancer	0.000952	0.00835	CbGpPWpGaD
Adenosine—Dermatitis—Etoposide—testicular cancer	0.000952	0.00138	CcSEcCtD
Adenosine—Headache—Etoposide—testicular cancer	0.000947	0.00137	CcSEcCtD
Adenosine—Chest pain—Methotrexate—testicular cancer	0.000944	0.00136	CcSEcCtD
Adenosine—Tension—Doxorubicin—testicular cancer	0.000942	0.00136	CcSEcCtD
Adenosine—Dysgeusia—Doxorubicin—testicular cancer	0.00094	0.00136	CcSEcCtD
Adenosine—Discomfort—Methotrexate—testicular cancer	0.000933	0.00135	CcSEcCtD
Adenosine—Nervousness—Doxorubicin—testicular cancer	0.000933	0.00135	CcSEcCtD
Adenosine—Syncope—Epirubicin—testicular cancer	0.000931	0.00135	CcSEcCtD
Adenosine—Back pain—Doxorubicin—testicular cancer	0.000929	0.00134	CcSEcCtD
Adenosine—Palpitations—Epirubicin—testicular cancer	0.000917	0.00133	CcSEcCtD
Adenosine—Loss of consciousness—Epirubicin—testicular cancer	0.000912	0.00132	CcSEcCtD
Adenosine—Cough—Epirubicin—testicular cancer	0.000906	0.00131	CcSEcCtD
Adenosine—Anaphylactic shock—Methotrexate—testicular cancer	0.000905	0.00131	CcSEcCtD
Adenosine—Vision blurred—Doxorubicin—testicular cancer	0.000905	0.00131	CcSEcCtD
Adenosine—Convulsion—Epirubicin—testicular cancer	0.000899	0.0013	CcSEcCtD
Adenosine—Nausea—Etoposide—testicular cancer	0.000898	0.0013	CcSEcCtD
Adenosine—Hypertension—Epirubicin—testicular cancer	0.000896	0.00129	CcSEcCtD
Adenosine—Chest pain—Epirubicin—testicular cancer	0.000884	0.00128	CcSEcCtD
Adenosine—Agitation—Doxorubicin—testicular cancer	0.000882	0.00128	CcSEcCtD
Adenosine—Anxiety—Epirubicin—testicular cancer	0.000881	0.00127	CcSEcCtD
Adenosine—Hyperhidrosis—Methotrexate—testicular cancer	0.000875	0.00126	CcSEcCtD
Adenosine—Discomfort—Epirubicin—testicular cancer	0.000873	0.00126	CcSEcCtD
Adenosine—Dry mouth—Epirubicin—testicular cancer	0.000864	0.00125	CcSEcCtD
Adenosine—Syncope—Doxorubicin—testicular cancer	0.000861	0.00124	CcSEcCtD
Adenosine—ADORA2B—Signaling Pathways—INSL3—testicular cancer	0.000857	0.00751	CbGpPWpGaD
Adenosine—Palpitations—Doxorubicin—testicular cancer	0.000849	0.00123	CcSEcCtD
Adenosine—Anaphylactic shock—Epirubicin—testicular cancer	0.000847	0.00122	CcSEcCtD
Adenosine—Hypotension—Methotrexate—testicular cancer	0.000846	0.00122	CcSEcCtD
Adenosine—Loss of consciousness—Doxorubicin—testicular cancer	0.000844	0.00122	CcSEcCtD
Adenosine—Cough—Doxorubicin—testicular cancer	0.000838	0.00121	CcSEcCtD
Adenosine—Shock—Epirubicin—testicular cancer	0.000833	0.0012	CcSEcCtD
Adenosine—Convulsion—Doxorubicin—testicular cancer	0.000832	0.0012	CcSEcCtD
Adenosine—Hypertension—Doxorubicin—testicular cancer	0.000829	0.0012	CcSEcCtD
Adenosine—Tachycardia—Epirubicin—testicular cancer	0.000827	0.00119	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000825	0.00119	CcSEcCtD
Adenosine—Hyperhidrosis—Epirubicin—testicular cancer	0.000819	0.00118	CcSEcCtD
Adenosine—Chest pain—Doxorubicin—testicular cancer	0.000818	0.00118	CcSEcCtD
Adenosine—Anxiety—Doxorubicin—testicular cancer	0.000815	0.00118	CcSEcCtD
Adenosine—Paraesthesia—Methotrexate—testicular cancer	0.000813	0.00117	CcSEcCtD
Adenosine—Discomfort—Doxorubicin—testicular cancer	0.000808	0.00117	CcSEcCtD
Adenosine—Dyspnoea—Methotrexate—testicular cancer	0.000807	0.00117	CcSEcCtD
Adenosine—Somnolence—Methotrexate—testicular cancer	0.000805	0.00116	CcSEcCtD
Adenosine—Dry mouth—Doxorubicin—testicular cancer	0.0008	0.00116	CcSEcCtD
Adenosine—Hypotension—Epirubicin—testicular cancer	0.000791	0.00114	CcSEcCtD
Adenosine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000784	0.00113	CcSEcCtD
Adenosine—Pain—Methotrexate—testicular cancer	0.000774	0.00112	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000772	0.00112	CcSEcCtD
Adenosine—ADORA2A—Signaling by NGF—KITLG—testicular cancer	0.000771	0.00676	CbGpPWpGaD
Adenosine—Shock—Doxorubicin—testicular cancer	0.000771	0.00111	CcSEcCtD
Adenosine—Tachycardia—Doxorubicin—testicular cancer	0.000765	0.00111	CcSEcCtD
Adenosine—Paraesthesia—Epirubicin—testicular cancer	0.000761	0.0011	CcSEcCtD
Adenosine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000758	0.00109	CcSEcCtD
Adenosine—Dyspnoea—Epirubicin—testicular cancer	0.000755	0.00109	CcSEcCtD
Adenosine—ADK—Metabolism—HPGDS—testicular cancer	0.000755	0.00662	CbGpPWpGaD
Adenosine—Somnolence—Epirubicin—testicular cancer	0.000753	0.00109	CcSEcCtD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000745	0.00654	CbGpPWpGaD
Adenosine—Hypotension—Doxorubicin—testicular cancer	0.000732	0.00106	CcSEcCtD
Adenosine—ADORA1—Signaling Pathways—INSL3—testicular cancer	0.000729	0.00639	CbGpPWpGaD
Adenosine—Pain—Epirubicin—testicular cancer	0.000724	0.00105	CcSEcCtD
Adenosine—Urticaria—Methotrexate—testicular cancer	0.000719	0.00104	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000714	0.00103	CcSEcCtD
Adenosine—Paraesthesia—Doxorubicin—testicular cancer	0.000704	0.00102	CcSEcCtD
Adenosine—Dyspnoea—Doxorubicin—testicular cancer	0.000699	0.00101	CcSEcCtD
Adenosine—Somnolence—Doxorubicin—testicular cancer	0.000697	0.00101	CcSEcCtD
Adenosine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000684	0.006	CbGpPWpGaD
Adenosine—Urticaria—Epirubicin—testicular cancer	0.000673	0.000972	CcSEcCtD
Adenosine—Pain—Doxorubicin—testicular cancer	0.00067	0.000969	CcSEcCtD
Adenosine—Hypersensitivity—Methotrexate—testicular cancer	0.000667	0.000964	CcSEcCtD
Adenosine—Asthenia—Methotrexate—testicular cancer	0.000649	0.000938	CcSEcCtD
Adenosine—Hypersensitivity—Epirubicin—testicular cancer	0.000624	0.000902	CcSEcCtD
Adenosine—Urticaria—Doxorubicin—testicular cancer	0.000623	0.0009	CcSEcCtD
Adenosine—Asthenia—Epirubicin—testicular cancer	0.000608	0.000878	CcSEcCtD
Adenosine—Dizziness—Methotrexate—testicular cancer	0.000599	0.000865	CcSEcCtD
Adenosine—Hypersensitivity—Doxorubicin—testicular cancer	0.000577	0.000834	CcSEcCtD
Adenosine—Vomiting—Methotrexate—testicular cancer	0.000575	0.000832	CcSEcCtD
Adenosine—ADORA2A—Signaling by NGF—FGFR3—testicular cancer	0.000573	0.00503	CbGpPWpGaD
Adenosine—Rash—Methotrexate—testicular cancer	0.000571	0.000825	CcSEcCtD
Adenosine—Dermatitis—Methotrexate—testicular cancer	0.00057	0.000824	CcSEcCtD
Adenosine—Headache—Methotrexate—testicular cancer	0.000567	0.000819	CcSEcCtD
Adenosine—ADORA2A—Signaling Pathways—INSL3—testicular cancer	0.000563	0.00493	CbGpPWpGaD
Adenosine—Asthenia—Doxorubicin—testicular cancer	0.000562	0.000813	CcSEcCtD
Adenosine—Dizziness—Epirubicin—testicular cancer	0.00056	0.000809	CcSEcCtD
Adenosine—ADK—Metabolism—STK11—testicular cancer	0.000549	0.00481	CbGpPWpGaD
Adenosine—Vomiting—Epirubicin—testicular cancer	0.000539	0.000778	CcSEcCtD
Adenosine—Nausea—Methotrexate—testicular cancer	0.000538	0.000777	CcSEcCtD
Adenosine—Rash—Epirubicin—testicular cancer	0.000534	0.000772	CcSEcCtD
Adenosine—Dermatitis—Epirubicin—testicular cancer	0.000534	0.000771	CcSEcCtD
Adenosine—Headache—Epirubicin—testicular cancer	0.000531	0.000767	CcSEcCtD
Adenosine—ADORA2A—Signaling by NGF—KIT—testicular cancer	0.000526	0.00462	CbGpPWpGaD
Adenosine—Dizziness—Doxorubicin—testicular cancer	0.000518	0.000749	CcSEcCtD
Adenosine—ADA—Metabolism—HPGDS—testicular cancer	0.000513	0.0045	CbGpPWpGaD
Adenosine—Nausea—Epirubicin—testicular cancer	0.000503	0.000727	CcSEcCtD
Adenosine—Vomiting—Doxorubicin—testicular cancer	0.000498	0.00072	CcSEcCtD
Adenosine—Rash—Doxorubicin—testicular cancer	0.000494	0.000714	CcSEcCtD
Adenosine—Dermatitis—Doxorubicin—testicular cancer	0.000494	0.000713	CcSEcCtD
Adenosine—Headache—Doxorubicin—testicular cancer	0.000491	0.00071	CcSEcCtD
Adenosine—DPP4—Metabolism of proteins—MMP2—testicular cancer	0.000485	0.00426	CbGpPWpGaD
Adenosine—Nausea—Doxorubicin—testicular cancer	0.000466	0.000673	CcSEcCtD
Adenosine—ADA—Metabolism—STK11—testicular cancer	0.000373	0.00327	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—H2AFZ—testicular cancer	0.000274	0.00241	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—STK11—testicular cancer	0.000273	0.00239	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—KITLG—testicular cancer	0.000252	0.00221	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—H2AFZ—testicular cancer	0.000233	0.00205	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—STK11—testicular cancer	0.000232	0.00203	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—KITLG—testicular cancer	0.000215	0.00188	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—FGFR3—testicular cancer	0.000188	0.00164	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—H2AFZ—testicular cancer	0.00018	0.00158	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—STK11—testicular cancer	0.000179	0.00157	CbGpPWpGaD
Adenosine—ADORA2B—Signaling Pathways—KIT—testicular cancer	0.000172	0.00151	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—KITLG—testicular cancer	0.000166	0.00145	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—FGFR3—testicular cancer	0.000159	0.0014	CbGpPWpGaD
Adenosine—ADORA1—Signaling Pathways—KIT—testicular cancer	0.000146	0.00128	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—FGFR3—testicular cancer	0.000123	0.00108	CbGpPWpGaD
Adenosine—ADORA2A—Signaling Pathways—KIT—testicular cancer	0.000113	0.000991	CbGpPWpGaD
